Daisy Michelle Princeton

Dr. Daisy Michelle Princeton


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2025
Verified
Book Chapter
Open access
PDF file
DPDaisy Michelle Princeton
Daisy Michelle Princeton
GYGülendam Hakverdioğlu Yönt
Gülendam Hakverdioğlu Yönt
SKSezer Kisa
Sezer Kisa
The use of physical restraints in healthcare is a complex and ethically sensitive practice that requires carefully balancing patient safety with respect for autonomy, dignity, and fundamental human rights. While restraints can sometimes be necessary to prevent immediate harm, their use carries substantial risks, including physical injury, psychological distress, diminished freedom, loss of personal autonomy, social isolation, a sense of abandonment, and erosion of trust in the therapeutic relationship. This chapter critically examines the ethical principles underpinning decisions about physical restraint, including beneficence, non-maleficence, autonomy, and justice, and highlights the tensions that arise when these principles conflict. It emphasizes individualized clinical assessments, challenges around informed consent, the role of multidisciplinary decision-making, and practical strategies for resolving ethical dilemmas. Furthermore, it underscores the need for strict adherence to legal and institutional policies to safeguard patient rights and ensure accountability. By adopting a reflective and rights-based approach, healthcare professionals can minimize restraint use, uphold ethical standards, and foster a culture of care that prioritizes dignity, compassion, and patient-centered practice.

11 January 2026 in International Wound Journal
Verified
Journal Article
Open access
UBUt T. Bui
Ut T. Bui
CPChristina Narelle Parker
Christina Narelle Parker
Jane A O'BrienJane A O'Brien
Jane A O'Brien
LHLinda Iren Mihaila Hansen
Linda Iren Mihaila Hansen
RGRosie Glynn
Rosie Glynn
DPDaisy Michelle Princeton
Daisy Michelle Princeton
Venous leg ulcers occur due to chronic venous insufficiency in the lower extremities and are often difficult to heal. Platelet‐rich plasma and platelet‐rich fibrin are products that contain high concentrations of platelets. This systematic review evaluated the effectiveness, safety and cost‐effectiveness of these products for the treatment of venous leg ulcers. Guided by the 2020 Joanna Briggs Institute systematic review of effectiveness guideline, this review included original studies that investigated platelet‐rich plasma and platelet‐rich fibrin in the treatment of venous leg ulcers from databases including the Cochrane Library, Embase, Medline, CINAHL, PubMed, World Health Organisation International Clinical Trials Registry, Clinical Trials.gov and Australian New Zealand Clinical Trials Registry. Methodological quality was assessed using relevant appraisal checklists. Information related to general characteristics of included articles and relevant outcomes of interest were extracted and synthesised narratively. Of thirty‐six eligible studies, 24 studies used platelet‐rich plasma, eleven investigated fibrin‐rich plasma and one study used both platelet‐rich plasma and fibrin‐rich. Most studies reported these products were effective in promoting wound healing, reducing other symptoms, and were safe to use. The use of platelet‐rich plasma and platelet‐rich fibrin resulted in significantly higher healed venous leg ulcers compared to control using conventional treatment (RR: 2.93, 95% CI, 1.90–4.53, p = 0.01). These products were safe to used topically and promoted to wound healing, reduced pain, either along or combined with other treatments. Platelet‐rich plasma and fibrin‐rich plasma improves wound healing and appears to be safe to use in the treatment of venous leg ulcers.